Department of Pharmaceutical , Usl Umbria 1, Via XIV Settembre 75, 06132, Perugia, Italy.
Department of Pharmaceutical , Asl Napoli 3 Sud, Dell'amicizia Street 22, Nola, 80035, Naples, Italy.
Mol Biol Rep. 2022 Jan;49(1):827-831. doi: 10.1007/s11033-021-06888-8. Epub 2021 Nov 27.
The global COVID-19 pandemic is currently underway. A massive worldwide vaccination campaign is still underway, representing the most promising weapon available to stop the pandemic.
However, research continues to investigate the most effective drug treatments to reduce and avoid the most serious complications caused by COVID-19 infection. Recently, new evidence of good therapeutic efficacy against COVID-19 has emerged for the antiviral Remdesivir and the immunomodulatory Baricitinib, also in combination. The first one showed SARS-CoV-2 antireplicative activity, the second one useful to reduce the hyperinflammatory state caused by cytokine storm in the most severe phases of the infection.
In this short communication we describe the molecular pharmacological mechanisms and the latest evidence for the use of these therapeutic agents in the treatment of COVID-19 infection.
全球 COVID-19 大流行仍在持续。目前，全球范围内正在开展大规模疫苗接种运动，这是阻止大流行最有希望的手段。
然而，研究仍在继续探索最有效的药物治疗方法，以减轻和避免由 COVID-19 感染引起的最严重并发症。最近，新的证据表明，抗病毒药物瑞德西韦和免疫调节剂巴利昔替尼联合使用具有良好的治疗 COVID-19 的疗效。前者显示出对 SARS-CoV-2 的抗病毒复制活性，后者可在感染的最严重阶段减少细胞因子风暴引起的过度炎症状态。
在这篇简短的通讯中，我们描述了这些治疗药物治疗 COVID-19 感染的分子药理学机制和最新证据。
